Hopes raised by new HIV treatment

High energy bills? Stay cool! #SummerEnergySavings

Compare energy deals and switch supplier to cut your bills by £447* and a chance to win a Dyson Cool Tower Fan!

in partnership with Banner uswitch

Looking to switch your business energy supplier? Click here

* Between 1 Jul 2018 and 31 Dec 2018, at least 10% of people who switched energy supplier for both gas & electricity with uSwitch saved £447 or more.

A new antiretroviral drug could "substantially" improve survival rates among people living with HIV, it has been claimed.

According to a Spanish study published today in the Lancet medical journal, a combination of the protease inhibitor darunavir and a low dose of existing antiretroviral drug ritonavir resulted in two-thirds of test subjects experiencing a tenfold reduction in HIV RNA levels – the genetic material that constitutes HIV.

In comparison, only 15 per cent of a control group of HIV sufferers receiving conventional treatments reached this proportion during the 48-week long study.

Dr Bonaventura Clotet of Barcelona's Hospital Universitari and his team say there is an "urgent need" for improved HIV-treating drugs due to the sizeable rates of failure in existing drug combinations.

The scientists say that over six-year periods, one in five HIV patients will be failed by their medication.

In an accompanying article, Dr Rodger MacArthur of Wayne State University in Detroit, Michigan cautioned that a further comparison between darunavir-ritonavir and tripranavir-ritonavir would be necessary to determine the true effectiveness of the new treatment.

But he added: "For now, all of us treating HIV-infected individuals in clinical practice will probably rejoice in the availability of darunavir, since it seems to be a safe, well-tolerated, and truly effective agent against multi-drug resistant HIV."

Click here to run an energy price comparison, and see if you could be paying less for your gas and electricity.

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more